Transcranial physical stimulation device for treating diseases related to deep target part of brain

By combining high-frequency oscillating electric field and near-infrared phototherapy in transcranial physical stimulation devices, targeted treatment for targeted deep areas such as the hippocampus, the inefficiency and discomfort of Alzheimer's disease treatment in the prior art is solved. sexual problems significantly reduce lesions and improve treatment effect.

CN118949276AActive Publication Date: 2024-11-15DANYANG HUICHUANG MEDICAL EQUIP CO LTD

Patent Information

Application Number
CN202411302687.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-15
Estimated Expiration
2044-09-19

AI Technical Summary

Technical Problem

The existing transcranial AC stimulation technology has inefficiency and discomfort for multiple brain regions when treating Alzheimer's disease, especially the difficulty of targeted treatment of the hippocampus, and the psychological pressure caused by electrode arrangement. and discomfort problems.

Method used

Using a transcranial physical stimulation device, combining the phototherapy part and the AC transcranial electric stimulation part, a high-frequency oscillating electric field is formed by arranging specific scalp electrodes on the scalp, and in conjunction with near-infrared phototherapy, it targets deep areas such as the hippocampus. Perform targeted therapy.

Benefits of technology

A gentle and comfortable treatment for multiple brain regions has been achieved, reducing the inflammatory mediators and Aβ plaque deposition of Alzheimer's disease, enhancing the phagocytic activity of microglia, reducing psychological stress, improving the comfort of treatment and Treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949276A_ABST
    Figure CN118949276A_ABST
Patent Text Reader

Abstract

A transcranial physical stimulation device for treating a disease associated with a deep target site of the brain includes at least a phototherapy portion configured to irradiate transcranial near-infrared light to at least the frontal lobe, temporal lobe, and apical lobe of a subject's head, and an alternating current transcranial electrical stimulation portion configured to irradiate transcranial near-infrared light to at least the frontal lobe, temporal lobe, and apical lobe of the subject's head. The alternating current transcranial electrical stimulation part comprises a first scalp electrode pair and a second scalp electrode pair, the first scalp electrode pair forms a first electric field and acts on a target deep part, and the second scalp electrode pair forms a second electric field and acts on the target deep part; the first electric field and the second electric field are simultaneously applied alternating current oscillation electric fields, the frequency is more than 1000Hz, and the frequency difference is 10Hz-80Hz. The device is convenient to operate, can perform comprehensive, mild and comfortable transcranial physical treatment on a plurality of brain areas related to AD, and can cooperate with transcranial alternating current (tACS) to perform targeted precise treatment on deep brain parts such as hippocampus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a transcranial physical stimulation device for treating brain diseases, and in particular to a transcranial physical stimulation device for treating diseases related to a target deep part of the brain. Background Art

[0002] With the development of population aging, AD (Alzheimer's disease) which is widely found in people over 65 years old is becoming a common challenge for society and families. The pathogenesis of AD is not fully understood, but the main pathological features generally recognized include extracellular neuritic plaques formed by the deposition of amyloid β protein and intracellular neurofibrillary tangles (NFTs) formed by the aggregation of hyperphosphorylated tau protein, and the degeneration and disappearance of a large number of neurons.

[0003] Among various AD treatment methods, tACS (transcranial alternating current stimulation) has recently become a safer non-invasive brain stimulation technology. It applies low-intensity alternating current of a specific frequency to the target area of ​​the brain through electrodes installed on the surface of the scalp, thereby regulating the brain's endogenous oscillations, such as the abnormal gamma oscillations in AD patients, and inducing the restoration of functional connections between brain regions.

[0004] The pathogenesis of AD is still unclear, and the lesions involve a wide range of brain areas, including the prefrontal lobe, temporal lobe, hippocampus, etc. After all, tACS is a type of electrical stimulation, and AD patients generally have a low acceptance of tACS in a wide range of brain areas. Arranging more electrodes on the heads of AD patients will increase the pressure on AD patients, and AD patients often suffer from mental and behavioral symptoms such as depression and anxiety, resulting in poor treatment compliance. The hair on the patient's head also makes it difficult to deploy more electrodes. If a conductive gel similar to an EEG electrode is used, it will increase the discomfort and resistance of AD patients. The tACS dose for a certain brain area is likely to act on an area that is not expected to be affected by the tACS dose. Doctors will worry about whether the specific electric field distribution of tACS in the skull meets the actual needs of AD patients. Summary of the invention

[0005] This application is proposed to solve the above technical problems in the prior art. This application aims to provide a transcranial physical stimulation device for treating diseases related to deep parts of the brain, including Alzheimer's disease, which is easy to operate and can perform comprehensive, gentle and comfortable transcranial physical treatment on multiple brain regions involved in AD, and can coordinate transcranial alternating current (tACS) to perform targeted and precise treatment on deep parts of the brain, such as the hippocampus.

[0006] According to the first scheme of the present application, a transcranial physical stimulation device for treating diseases related to a target deep part of the brain is provided. The transcranial physical stimulation device includes at least a phototherapy unit and an alternating current transcranial electrical stimulation unit, and the phototherapy unit is configured to irradiate transcranial near-infrared light to at least the frontal lobe, temporal lobe and parietal lobe of the subject's head. The alternating current transcranial electrical stimulation unit includes a first scalp electrode pair and a second scalp electrode pair, the first scalp electrode pair includes a first electrode and a second electrode, the first electrode is arranged at the scalp near the first side temporal lobe, and the second electrode is arranged at the scalp more anterior to the first electrode, so that a first electric field is formed between the first electrode and the second electrode and acts on the target deep part. The second scalp electrode pair includes a third electrode and a fourth electrode, the third electrode is arranged at the scalp near the other side temporal lobe, and the fourth electrode is arranged at the scalp more anterior to the third electrode, so that a second electric field is formed between the third electrode and the fourth electrode and acts on the target deep part, and the first electric field and the second electric field are alternating current oscillating electric fields applied simultaneously, with a frequency of more than 1000 Hz and a frequency difference of 10 Hz-80 Hz.

[0007] According to the second scheme of the present application, a transcranial physical stimulation device for treating diseases related to a target deep part of the brain is provided. The phototherapy unit also includes a head cap, and a plurality of near-infrared light source assemblies are arranged inside the head cap, and the plurality of near-infrared light source assemblies are configured to emit pulsed light to the treatment object, and the wavelength of the pulsed light is 620nm-1080nm, and the radiation range of the pulsed light of each near-infrared light source assembly includes at least part of the hippocampus and overlaps at the hippocampus to form a second overlapping area.

[0008] Compared with the prior art, the beneficial effects of the embodiments of the present application are: the phototherapy unit can cooperate with the AC transcranial electrical stimulation unit to irradiate a wide range of brain areas with near-infrared light with mild energy. The irradiation is mild and comfortable, and the psychological pressure of the irradiated object is relatively small. By conveniently attaching scalp electrodes at a few locations, AC transcranial electrical targeted intensive stimulation can be performed on the target deep parts such as the hippocampus. The electrodes are arranged in areas with less hair, which is convenient for convenient adaptation according to the location of the target deep parts. In this way, not only the diffuse shallow lesion tissue is treated attentively, but also the concentrated and deep target deep parts are targeted and intensively stimulated. Further, the extensive irradiation of the diffuse shallow lesion tissue with transcranial near-infrared light can widely reduce or even eliminate the diffuse shallow lesions. For example, for Alzheimer's disease, inflammatory mediators are reduced, the deposition of Aβ plaques is reduced, and the exogenous oscillation-neural entrainment mechanism is used to focus on the target deep parts, and comprehensive treatment is performed from the treatment mechanism and the lesions of different courses. The object feels more comfortable and has less psychological pressure during the treatment process.

[0009] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application, it can be implemented in accordance with the contents of the specification. In order to make the above description and other purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are listed below. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] In the drawings, which are not necessarily drawn to scale, the same reference numerals may describe similar parts in different views. Similar reference numerals with letter suffixes or different letter suffixes may represent different examples of similar components. The accompanying drawings generally illustrate various embodiments by way of example and not by way of limitation, and together with the description and claims, are used to illustrate the disclosed embodiments. Such embodiments are illustrative and exemplary and are not intended to be exhaustive or exclusive embodiments of the present method, apparatus, system, or non-transitory computer-readable medium having instructions for implementing the method.

[0011] FIG. 1( a ) shows a schematic left side view of a transcranial physical stimulation device for treating diseases related to a target deep part of the brain according to an embodiment of the present application;

[0012] FIG1( b ) shows a schematic right side view of a transcranial physical stimulation device for treating diseases related to a target deep part of the brain according to an embodiment of the present application;

[0013] FIG. 2( a ) shows a first example of an electrode configuration of a transcranial physical stimulation device according to an embodiment of the present application;

[0014] FIG2( b ) shows a second example of the electrode configuration of the transcranial physical stimulation device according to an embodiment of the present application;

[0015] FIG2( c ) shows a third example of the electrode configuration of the transcranial physical stimulation device according to an embodiment of the present application;

[0016] FIG2( d ) shows a fourth example of the electrode configuration of the transcranial physical stimulation device according to an embodiment of the present application;

[0017] Figure 3 A superimposed envelope diagram showing the AC oscillating electric field - the first electric field and the second electric field applied simultaneously according to an embodiment of the present application; and

[0018] Figure 4 A diagram showing the radiation range of the light therapy part of the transcranial physical stimulation device relative to the hippocampus according to an embodiment of the present application. DETAILED DESCRIPTION

[0019] In order to enable those skilled in the art to better understand the technical solution of the present application, the present application is described in detail below in conjunction with the accompanying drawings and specific implementation examples. The embodiments of the present application are further described in detail below in conjunction with the accompanying drawings and specific implementation examples, but are not intended to limit the present application.

[0020] The words "first", "second" and similar words used in this application do not indicate any order, quantity or importance, but are only used to distinguish. The words "include" or "comprises" and similar words used in this application mean that the elements before the word include the elements listed after the word, and do not exclude the possibility of covering other elements. In this application, the arrows shown in the figures of each step are only examples of the execution order, not limitations. The technical solution of this application is not limited to the execution order described in the embodiments. The various steps in the execution order can be combined, decomposed, or the order can be changed, as long as the logical relationship of the execution content is not affected.

[0021] All terms (including technical terms or scientific terms) used in this application have the same meaning as those understood by ordinary technicians in the field to which this application belongs, unless otherwise specifically defined. It should also be understood that terms defined in general dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an idealized or extremely formal sense, unless explicitly defined here. Techniques and equipment known to ordinary technicians in the relevant field may not be discussed in detail, but where appropriate, the techniques and equipment should be considered as part of the specification.

[0022] FIG. 1( a) and FIG. 1( b) respectively show a schematic left side view and a schematic right side view of a transcranial physical stimulation device for treating diseases related to a target deep part of the brain according to an embodiment of the present application. The so-called diseases related to the deep part of the brain used to treat the present invention are intended to indicate that the disease is related to the deep part of the brain, such as at least one of the basal ganglia, thalamus, amygdala, hippocampus, and nerve nucleus. For example, AD is closely associated with the hippocampus. For another example, anxiety and post-traumatic stress disorder (PTSD) are both associated with the amygdala. For another example, post-stroke cognitive impairment (PSCI) and thalamic dementia are associated with the thalamus. The so-called transcranial physical stimulation device is intended to indicate that the applied light, electricity, magnetism and other physical stimuli still have a physical stimulation amount after being attenuated by the skull, and can act on the brain tissue below the skull, at least on the cortex. Brain tissues are from shallow to deep, such as the cerebral cortex, white matter, basal ganglia, thalamus, hypothalamus, etc. For example, the hippocampus is located in the temporal lobe of the brain, close to the medial temporal lobe, and is part of the limbic system. It is located in the deep structures of the brain, but not as deep as the basal ganglia, thalamus, or brainstem. The hippocampus is usually considered to be a subcortical structure in anatomical terms.

[0023] As shown in Figures 1(a) and 1(b), the transcranial physical stimulation device includes at least a phototherapy unit 101 and an alternating current transcranial electrical stimulation (tACS) unit 102. Please note that for the sake of simplicity of the diagram, only the head cap of the phototherapy unit 101 and the scalp electrode sheet of the alternating current transcranial electrical stimulation unit 102 are shown, and structures such as the cables and the host device to which the cables are connected are not shown. For example, the phototherapy unit 101 may include an array of LED light panels distributed in the head cap to emit transcranial near-infrared light to multiple parts of the subject's head, and these LED light panels can be powered externally via cables to light up LED lamp beads to emit transcranial near-infrared light. For another example, the phototherapy unit 101 may include an array of optical fiber bundles introduced into the head cap, and the optical fiber bundles can transmit near-infrared light from an external light source (such as but not limited to a near-infrared light excitation generator) via an optical cable.

[0024] The phototherapy unit 101 is configured to irradiate transcranial near-infrared light to at least the frontal lobe, temporal lobe and parietal lobe of the subject's head. For diseases related to the target deep part of the brain, before the onset of clinical symptoms or during the development of the disease, the lesions are not limited to the target deep part of the brain, but also frequently occur in more shallow parts of the frontal lobe, temporal lobe and parietal lobe.

[0025] Let’s take Alzheimer’s disease as an example.

[0026] Alzheimer's disease is a brain disease associated with the hippocampus deep in the brain. Extensive Aβ plaque deposition in the cerebral cortex and neurofibrillary tangles caused by tau protein lesions in the cortex are significant pathological hallmarks of Alzheimer's disease. The precipitation of Aβ plaques triggers a chain reaction, which in turn leads to the misfolding and assembly of tau protein in the cell, which in turn spreads the lesions to a wider range of neural circuits and cortex, ultimately leading to the failure of the nervous system and the decline of cognitive ability. Many years before the clinical symptoms of Alzheimer's disease appear, Aβ plaques have accumulated in the medial prefrontal and parietal regions of the neocortex, and Tau protein will also begin to accumulate in the middle temporal lobe of the inner cortex, and then gradually spread to the hippocampus and limbic cortex. The deposition of Aβ plaques and the progression of Tau protein aggregation also reflect the development of the course of Alzheimer's disease to a certain extent.

[0027] Furthermore, neuroinflammation also plays an important role in the development of Alzheimer's disease. Neuroinflammation refers to the activation of the brain's immune response, involving immune cells such as microglia and astrocytes. In a healthy state, neuroinflammation plays a beneficial role in maintaining brain homeostasis and defending against infection or injury; in the brains of patients with Alzheimer's disease, this inflammatory response becomes chronic and dysregulated, leading to harmful consequences such as neuronal damage, even before symptoms appear. Neuroinflammation is closely related to the accumulation of amyloid beta (Aβ) plaques and neurofibrillary tangles caused by hyperphosphorylated tau protein. Microglia and astrocytes are resident immune cells in the brain and play a key role in regulating neuroinflammation in Alzheimer's disease. After the accumulation of Aβ plaques, microglia and astrocytes will change from the M1 / A1 phenotype to the M2 / A2 phenotype, thereby losing their protective function, resulting in the production of proinflammatory cytokines and aggravating neuroinflammation. In addition, the phagocytic function of microglia is impaired, resulting in reduced clearance of Aβ plaques, further producing neurotoxicity. These two types of glial cells are widely distributed in the brain from the cortex to deep structures such as the hippocampus, which leads to the diffuse distribution of inflammatory mediators during the course of Alzheimer's disease, which occurs in the frontal, temporal and parietal lobes of the cortex before symptoms appear.

[0028] For such multi-focal diffusely distributed brain diseases, such as Alzheimer's disease, by irradiating at least the frontal, temporal and parietal lobes of the subject's head with an appropriate dose of transcranial near-infrared light, a comprehensive, gentle and comfortable effective treatment can be provided for shallower diffuse lesions in the deeper parts of the target. Specifically, irradiating the frontal, temporal and parietal lobes of the subject's head with an appropriate dose of transcranial near-infrared light can significantly reduce the accumulated volume and number of Aβ plaques in the cerebral cortex and hippocampus, reduce the level of inflammation, upregulate the corresponding stress response proteins in the brain, reduce protein aggregation and neuronal apoptosis, and enhance the phagocytic activity of accumulated Aβ plaques such as microglia, thereby alleviating the progression of Alzheimer's disease.

[0029] The scalp electrode sheets of the AC transcranial electrical stimulation unit 102 are paired, including a first scalp electrode pair and a second scalp electrode pair. The first scalp electrode pair includes a first electrode e1 and a second electrode e2, wherein the first electrode e1 is arranged at the scalp near the first temporal lobe, and the second electrode e2 is arranged at the scalp more anterior than the first electrode, so that a first electric field E1 is formed between the first electrode and the second electrode and acts on the target deep part. The second scalp electrode pair includes a third electrode e4 and a fourth electrode e3, wherein the third electrode e4 is arranged at the scalp near the other temporal lobe, and the fourth electrode e3 is arranged at the scalp more anterior than the third electrode e4, so that a second electric field E2 is formed between the third electrode e4 and the fourth electrode e3 and acts on the target deep part. The first electric field E1 and the second electric field E2 are AC oscillating electric fields applied simultaneously, with a frequency of more than 1000Hz and a frequency difference of 10Hz-80Hz.

[0030] Such electrodes are arranged near the temporal lobe or more forward, such as near the temporal hairline, behind the ears, forehead, etc., where there is less hair and it is easy to be exposed (for example, shaving a part of the hairline does not affect the appearance much), such as shown in Figure 1 (a) and Figure 1 (b), which makes it easier to attach and remove, and it is also more convenient and comfortable to wipe off when using conductive gel. In addition, because the electrode sheets are arranged in areas with less hair, they are also convenient to adapt according to the location of the target deep part, such as the electrode configurations shown in Figures 2 (a), 2 (b), 2 (c) and 2 (d), which can accurately target and enhance the treatment of different target deep parts, which will be described in detail below.

[0031] The electrode arrangement of Figures 1(a) and 1(b) is used as an example for explanation, and Figure 2(a) shows this electrode arrangement in comparison with the MRI image of the head. Electrode e1 and electrode e2 are a pair, and electrode e3 and electrode e4 are a pair. As shown in Figure 2(a), electrode e1 is arranged around the ear on the left side, and electrode e2 is arranged on the right side of the frontal part adjacent to the temporal lobe; electrode e3 is arranged around the ear on the left side, separated from electrode e1 on both sides of the upper edge of the helix, and electrode e4 is arranged on the right side of the occipital part adjacent to the temporal lobe. The hair around the ear is also sparse, and the hair near the frontal lobe and the temporal lobe are relatively sparse, making it easy to attach electrodes and clean. For the hippocampus, in some embodiments, the two electrode sheets at the ear can be arranged basically symmetrically on both sides of the upper edge of the helix, and the spacing can be 4-6cm, which just corresponds to the front and back of the hippocampus.

[0032] The paired electrode sheets e1-e2 can be connected to a corresponding current source I1 of an alternating sinusoidal waveform to generate an oscillating first electric field in the brain between the pair of electrode sheets, denoted as E1, and the paired electrode sheets e3-e4 can be connected to a corresponding current source I2 of an alternating sinusoidal waveform to generate an oscillating second electric field in the brain between the pair of electrode sheets, denoted as E2. The first electric field E1 and the second electric field E2 can be superimposed at the elongated target deep part on the left side - the hippocampus, and the superimposed area is shown as the white circle in Figure 2(a). Here, a sinusoidal current source is used as an example, but it should be noted that the waveform of the current is not limited to this, and may also include other waveforms such as square waves.

[0033] The first electric field E1 and the second electric field E1 are AC oscillating electric fields applied simultaneously, with a frequency of more than 1000 Hz and a frequency difference of 10 Hz-80 Hz, so that a beat frequency phenomenon can be formed, that is, a phenomenon generated when two sine waves or periodic signals with similar but different frequencies are superimposed. When the frequency difference between the two signals is small, a low-frequency oscillation envelope can be observed, and the frequency of this oscillation is equal to the difference between the frequencies of the two original signals.

[0034] The first electric field E1 and the second electric field E2 are two signals with very close frequencies, such as sinusoidal waves, with frequencies f1 and f2, f2>f1. Both frequencies are greater than 1000Hz, and can even be several thousand Hz. The frequency difference Δf=f2-f1 is several Hz to tens of Hz. The two signals E1 and E2 are superimposed in the overlapping area. The frequency difference is small enough relative to the frequency. After superposition, a low-frequency oscillating electric field E will be obtained. The envelope curve obtained after superposition is as follows Figure 3 As shown, the intensity distribution curve of the low-frequency oscillation synthetic wave is also shown. The frequency of the low-frequency oscillation is Δf, and the frequency of the low-frequency oscillation can also be changed by adjusting the frequency difference.

[0035] Although two high-frequency oscillating electric fields with a frequency of more than 1000Hz are applied, the cells in the area where the two electric fields do not overlap will not be activated, and the neurons will not respond to it. Because neurons only respond to low-frequency signals <100Hz and are not affected by high-frequency signals >1KHz, this allows the high-frequency electric field signal to reach the deep part of the target without causing any impact on the neurons in the superficial areas such as the cortex and sub-cortex along the way. In the deep part of the target, the low-frequency oscillating electric field signal obtained by superimposing two high-frequency electric field signals with a frequency difference of Δf has a frequency range that effectively acts on neurons, regulates endogenous oscillations in the brain, forms neural entrainment, and thereby regulates neural activity and induces the recovery of functional connections between brain regions.

[0036] Sufficient energy can be introduced through high-frequency electric field signals, and the energy has no effect on cells and neurons in a single high-frequency electric field signal pathway, and is not consumed in unexpected superficial areas, nor stimulated in unexpected superficial areas. Instead, two high-frequency electric field signals with a frequency difference of Δf form a low-frequency oscillating electric field with a frequency difference that cells and neurons are sensitive to in the overlapping area, thereby efficiently focusing sufficient energy on the target deep part located in the overlapping area, such as the hippocampus, thereby ensuring accurate targeted doses.

[0037] Different from relying solely on near-infrared radiation to reach deep target areas such as the hippocampus, the phototherapy unit 101 of the present application can cooperate with the AC transcranial electrical stimulation unit 102 to irradiate a wide range of brain areas with near-infrared light with mild energy. The irradiation is gentle and comfortable, and the psychological pressure on the irradiated object is relatively small. By conveniently attaching scalp electrodes in a few positions, AC transcranial electricity can be targeted for enhanced stimulation of deep target areas such as the hippocampus. In this way, not only the diffuse shallow lesion tissue is treated attentively, but also the concentrated and deep target deep areas are targeted for enhanced stimulation. Further, the extensive irradiation of diffuse shallow lesion tissue with transcranial near-infrared light can widely reduce or even eliminate diffuse shallow lesions. For example, for Alzheimer's disease, inflammatory mediators are eliminated, the deposition of Aβ plaques is reduced, and the exogenous oscillation-neural entrainment mechanism is used to focus on the deep target areas. The present application uses a rich treatment mechanism to carry out comprehensive treatment for lesions of different courses, and the subject feels more comfortable and has less psychological pressure during the treatment process.

[0038] Please note that FIG2(a) is only an example of an electrode arrangement that is particularly suitable for treating Alzheimer's disease and for focused targeted stimulation of the hippocampus with transcranial alternating current. Figure 2(a)-Figure 2(d) As shown, there is a hippocampus in each of the left and right cerebral hemispheres, which is C-shaped and slender and is located between the thalamus and the medial temporal lobe on the corresponding side. Returning to Figure 2(a), in the course of Alzheimer's disease, the lesions of the hippocampus are usually not symmetrical. Through the arrangement of the electrodes shown, the two electrodes e1 and e3 around the ear can be staggered and arranged on the side to stimulate the hippocampus, and these two electrodes can be used as positive electrodes, so that the positive electrode is closer to the hippocampus to be stimulated, so that the electric field spreads less, and the electric field strength and current strength acting on the hippocampus can be greater.

[0039] Moreover, for the elongated hippocampus on each side, partial focused stimulation of the hippocampus can also be performed. The main extension direction of the hippocampus is called the longitudinal direction, and a single hippocampus can be divided into several longitudinal target parts, such as the longitudinal front part, the longitudinal middle part, the longitudinal rear part, etc. For example, among electrodes e1 and e3, the former corresponds to the longitudinal front part, and the latter corresponds to the longitudinal middle part. If the longitudinal front part is focused on, the stimulation current amplitude of electrode e3 can be made larger than the stimulation current amplitude of electrode e1, that is, the stimulation current of the electrode corresponding to the longitudinal target part is smaller than the stimulation current of the electrode corresponding to other parts of the hippocampus. Thus, the focal area of ​​transcranial electrical stimulation can be guided to the longitudinal front part, thereby achieving precise targeted intensive treatment of the deep target parts, and even the positioning of the target area can be flexibly adjusted.

[0040] In some embodiments, the current of the first scalp electrode pair 102 and the second scalp electrode pair 102 is adjustable within the range of 0-10 mA. Specifically, by adjusting the relative current magnitude of the first scalp electrode pair 102 and the second scalp electrode pair 102, the position of the target area can be flexibly adjusted. For example, in the electrode arrangement of FIG. 1(a) and FIG. 1(b), by adjusting the relative current magnitude of the first scalp electrode pair 102 and the second scalp electrode pair 102, even the target area can be flexibly adjusted to traverse the various longitudinal divisions of the hippocampus on the side where the electrodes e1 and e3 are located.

[0041] The arrangement of electrodes for the hippocampus is not limited to this, and other arrangements may also be used.

[0042] As shown in FIG2(b), the two positive electrodes e1 and e3 can be arranged near the ear on the side where the hippocampus to be stimulated is located, and the corresponding two negative electrodes e2 and e4 can be arranged near the ear on the opposite side. It can be seen that e2 as the second electrode is in front of e1 as the first electrode, and e3 as the fourth electrode is in front of e4 as the third electrode, and the third electrode e4 is on the opposite side of the first electrode e1. In this way, the high-frequency first electric field E1 and the second electric field E2 intersect in a cross manner, and the intersection is the overlapping area, and the overlapping area forms a low-frequency oscillating electric field E. If a part of the hippocampus is to be stimulated, the high-frequency first electric field E1 and the second electric field E2 can be cross-overlapped at the stimulated part. This method can form a target area that extends more in the longitudinal direction of the hippocampus and is more restricted in the transverse direction perpendicular to the longitudinal direction.

[0043] As shown in FIG2(c), a positive electrode e3 (as the fourth electrode) and a negative electrode e1 (as the first electrode) can also be arranged near the ear on the side where the hippocampus to be stimulated is located. The positive electrode e2 (as the second electrode) corresponding to the negative electrode e1 can be an electrode on the forehead across the left and right sides of the forehead to form a first electric field that enters from the forehead and passes through the ear side, and the negative electrode e4 (as the third electrode) corresponding to the positive electrode e3 can be arranged near the forehead of the other side of the temporal lobe. It can be seen that the third electrode e4 is on the opposite side of the first electrode e1 and behind the fourth electrode e3. Thus, a second electric field with an electric field direction opposite to the first electric field is formed. This method can form a targeted area that is tilted relative to the hippocampus.

[0044] As described above, in addition to the hippocampus, the deep part of the brain may include at least one of the basal ganglia, thalamus, amygdala, and nerve nucleus. Taking the thalamus as an example, as shown in FIG2(d), the two positive electrodes e2 and e3 in FIG2(a) (respectively as the second electrode and the fourth electrode) can be changed to the same electrode and arranged on the left and right sides of the forehead across the forehead, and the two negative electrodes e1 and e4 (respectively as the first electrode and the third electrode) are arranged at the mastoids behind the ears on both sides. It can be seen that the second electrode and the fourth electrode e2 / e3 are in front of the first electrode e1 and the third electrode e4, and the third electrode e4 is on the opposite side of the first electrode e1. In this way, the overlapping area of ​​the first electric field and the second electric field formed can be located in the thalamus to achieve targeted and precise treatment of the thalamus.

[0045] In some embodiments, the light therapy unit 101 is at a first frequency f1 ’ Irradiate transcranial near-infrared light, the first frequency f1 ’ The frequency difference Δf between the first electric field and the second electric field is less than the first threshold. In this way, the first frequency f1 of the near-infrared light can be ’ As close as possible to the frequency Δf of the synthetic low-frequency electric field E. For example, when the frequency difference Δf between the first electric field and the second electric field is 40 Hz, the first frequency f1 ’ It can also be 40Hz. The action frequency of light therapy and the action frequency of transcranial alternating current stimulation are the same frequency or close to the same frequency, which can significantly enhance the neural entrainment effect and strengthen the treatment effect.

[0046] For example, the first frequency f1 ’ The frequency difference Δf between the two electric fields can be the same frequency among 10Hz, 20-40Hz and 75-80Hz. The same frequency can significantly improve the matching and strengthening of oscillations, enhance the neural entrainment effect, and enhance the therapeutic effect.

[0047] Especially at 40Hz, the photoelectric combined stimulation at a frequency of 40Hz can synergistically improve the condition of Alzheimer's patients from multiple aspects: promoting the exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF) in Alzheimer's patients, playing a positive role in p-Tau protein deposition, accelerating the lymphatic clearance of amyloid protein, inducing endogenous EEG oscillations to produce entrainment through external current, stimulating and improving gamma oscillations, and specifically regulating the neural network in the damaged area. Improve the neural oscillations and brain functional connections in the damaged area, promote brain function improvement, enhance the patient's cognitive ability, and delay the course of the disease.

[0048] In some embodiments, each electrode is a flexible transparent electrode so as to be attached to the curved scalp, such as the forehead, the mastoid processes on both sides, and near the helix, and the transcranial light radiation of the phototherapy part is basically not blocked, so that the transcranial light can still act efficiently on the frontal lobe and temporal lobe. It should be noted that the location where the scalp electrode is attached in the present application, such as the temporal lobe and the vicinity of the frontal lobe, is an important area for near-infrared light irradiation. By adopting the transmission and close contact of the flexible transparent electrode, the attenuation of the near-infrared light on the optical path of the electrode and the electrode-scalp connection area can be reduced, thereby ensuring the desired irradiation dose distribution in the important area.

[0049] Various flexible transparent electrodes can be used, such as but not limited to flexible nano-metal mesh transparent electrodes, silver nanowire embedded silk protein electrodes, nanofiber-based flexible transparent electrodes, etc. The flexible transparent electrode can be 2cm 2 -4cm 2 The shape of the flexible transparent electrode can be a rounded rectangle or a circle, and can be different according to the exposed area of ​​the scalp to be adhered. For example, the flexible transparent electrode on the forehead can adopt a larger area, and the flexible transparent electrode at the mastoid can adopt a smaller area, so as to ensure sufficient adhesion while ensuring the stimulation current and avoiding folding or detachment of the electrode as much as possible.

[0050] In some embodiments, each electrode is attached to the scalp via a conductive transparent gel, and the transmittance of the conductive transparent gel to near-infrared light of 620nm-1080nm is maintained at 70%-90%. For example, such a conductive transparent gel can be used, which is non-sensitive and firm to stick, and painless to peel off. Specifically, a conductive transparent gel can be used that is triggered by body temperature and automatically and painlessly peeled off when the temperature drops.

[0051] This conductive transparent gel can be prepared based on the polyphenol-protein complexation strategy. For example, as follows. First, a polyphenol prepolymer (PGA) rich in phenolic and quinone groups is formed; secondly, the multiple interactions of polyphenol groups are used in the gelation process of double-bonded gelatin (GelMA) to break the hydrogen bonding between GelMA molecular chains, adjust the entanglement density of GelMA chains to make it temperature-responsive, and achieve stability under body temperature conditions and enhance the fluidity of molecular chains. When the hydrogel comes into contact with human skin, body temperature triggers a phase change, achieving efficient and rapid adhesion, and maintaining stability for a long time. After a simple cooling of the hydrogel surface, hydrogen bonds are regenerated between the GelMA molecular chains in the network, the adhesion force is reduced, and non-damage peeling is achieved. Furthermore, the introduction of PGA adjusts the cross-linking mode of the GelMA network, giving the PGA-GelMA hydrogel mechanical flexibility and high ductility that match the skin tissue, avoiding damage caused by pulling the hydrogel when peeling off the skin surface. In addition, the PGA-GelMA hydrogel also exhibits excellent anti-inflammatory, antioxidant, anti-allergic and other biological activities, which can effectively avoid skin irritation or allergies caused by traditional skin adhesives in long-term contact with the skin.

[0052] For another example, a highly transparent, self-adhesive and thermally responsive conductive hydrogel based on dopamine-triggered gelation can be used. On the one hand, dopamine acts as an initiator to initiate the polymerization of monomers to form a polymer backbone, and on the other hand, it can act as a non-covalent cross-linking agent to dynamically adjust the cross-linking network of the hydrogel using intermolecular forces. The dopamine content is as high as 50%, and it can maintain a transmittance of 70%-90% for near-infrared light.

[0053] Now returning to FIG. 1( a ) and FIG. 1( b ), the phototherapy unit 101 further comprises a head cap, and a plurality of near-infrared light source assemblies (such as Figure 4 As shown in 401 in the figure, the multiple near-infrared light source assemblies 401 are configured to emit pulsed light to the treatment object, the wavelength of the pulsed light is 620nm-1080nm, and the radiation range of the pulsed light of each near-infrared light source assembly 401 includes at least a part of the hippocampus, and the near-infrared light is with sufficiently large power to act deep under the dura mater and on the hippocampus, and overlap at the hippocampus to form a second overlapping area.

[0054] In some embodiments, the pulsed light of each near-infrared light source assembly 401 can be combined to radiate a second overlapping area that can overlap with the action area of ​​the first electric field or the second electric field (eg, Figure 2(a)-Figure 2(d)) at least partially overlap. This is particularly applicable to situations where the lesions of brain diseases develop to the deep part of the target. Taking Alzheimer's disease as an example, early Aβ plaques accumulate in the medial prefrontal and parietal regions of the neocortex, and Tau protein also begins to accumulate in the middle temporal lobe of the endocortex, and then gradually spreads to the hippocampus, showing significant deposition in the hippocampus. In this way, the targeted focusing of focused light therapy and transcranial alternating current stimulation is synergistically performed on the hippocampus. The former can reduce plaque deposition and inflammation in the hippocampus, and the latter regulates the rhythm of endogenous oscillations in the brain, forming neural entrainment to achieve neural regulation; further, the focused irradiation of pulsed light in all directions, coordinated with the targeted enhancement of transcranial alternating current stimulation, can ensure sufficient photoelectric synergistic dose in the hippocampus, especially for the treatment of Alzheimer's disease in the middle and late stages.

[0055] In addition, although exemplary embodiments have been described herein, the scope includes any and all embodiments based on the present application with equivalent elements, modifications, omissions, combinations (e.g., various embodiments intersecting schemes), adaptations or changes. The elements in the claims will be interpreted broadly based on the language adopted in the claims, and are not limited to the examples described in this specification or during the implementation of the application, and the examples will be interpreted as non-exclusive. Therefore, this specification and examples are intended to be considered as examples only, and the true scope and spirit are indicated by the following claims and the full scope of their equivalents.

[0056] The above description is intended to be illustrative rather than restrictive. For example, the above examples (or one or more of them) can be used in combination with each other. For example, those of ordinary skill in the art can use other embodiments when reading the above description. In addition, in the above-mentioned specific embodiments, various features can be grouped together to simplify the application. This should not be interpreted as an intention that a disclosed feature that does not require protection is necessary for any claim. On the contrary, the subject matter of the present application may be less than all the features of a specific disclosed embodiment. Thus, the claims are incorporated into the specific embodiments as examples or embodiments, wherein each claim is independently used as a separate embodiment, and it is considered that these embodiments can be combined with each other in various combinations or arrangements. The scope of the present application should be determined with reference to the full scope of the equivalent forms of the attached claims and these claims.

[0057] The above embodiments are only exemplary embodiments of the present application and are not intended to limit the present application. The protection scope of the present application is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present application within the essence and protection scope of the present application, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present application.

Claims

1. A transcranial physical stimulation device for treating diseases related to a target deep part of the brain, characterized in that: The transcranial physical stimulation device includes at least a phototherapy section and an alternating current transcranial electrical stimulation section, the phototherapy section being configured to irradiate transcranial near-infrared light to at least the frontal lobe, the temporal lobe, and the parietal lobe of the subject's head; The AC transcranial electrical stimulation unit includes a first scalp electrode pair and a second scalp electrode pair, wherein the first scalp electrode pair includes a first electrode and a second electrode, wherein the first electrode is arranged on the scalp near the first temporal lobe, and the second electrode is arranged on the scalp more anterior than the first electrode, so that a first electric field is formed between the first electrode and the second electrode and acts on a target deep part; The second scalp electrode pair includes a third electrode and a fourth electrode, the third electrode is arranged on the scalp near the other side of the temporal lobe, and the fourth electrode is arranged on the scalp more anterior than the third electrode, so that a second electric field is formed between the third electrode and the fourth electrode and acts on the deep target part, and the first electric field and the second electric field are AC oscillating electric fields applied simultaneously, with a frequency above 1000 Hz and a frequency difference of 10 Hz-80 Hz.

2. The transcranial physical stimulation device according to claim 1, characterized in that: The phototherapy unit irradiates transcranial near-infrared light at a first frequency, and the frequency difference between the first frequency and the first electric field and the second electric field is less than a first threshold.

3. The transcranial physical stimulation device according to claim 1, characterized in that: The second electrode and the fourth electrode are the same electrode and are arranged on the forehead across the left and right sides of the forehead, and the first electrode and the third electrode are arranged at the mastoid processes behind the ears on both sides.

4. The transcranial physical stimulation device according to claim 1, characterized in that: One of the first electrode and the second electrode is arranged around the ear on one side, and the other is arranged at the forehead or occipital region near the temporal lobe on the other side; one of the third electrode and the fourth electrode is arranged around the ear on the same side, and the other is arranged at the forehead or occipital region near the temporal lobe on the other side.

5. The transcranial physical stimulation device according to claim 4, characterized in that: The disease related to the target deep site includes Alzheimer's disease, the target deep site includes the hippocampus on the first side, and the periauricular electrode is located at the periauricular area of ​​the first side and serves as an anode.

6. The transcranial physical stimulation device according to claim 5, characterized in that: The target deep part includes a longitudinal target part of the hippocampus, and the stimulation current of the electrodes around the ear corresponding to the longitudinal target part is smaller than the stimulation current of the electrodes corresponding to other parts of the hippocampus.

7. The transcranial physical stimulation device according to claim 3, characterized in that: The target deep site includes the thalamus.

8. The transcranial physical stimulation device according to any one of claims 1 to 6, characterized in that: The current of the first scalp electrode pair and the second scalp electrode pair is adjustable within the range of 0-10 mA, and the deep brain area includes the hippocampus.

9. The transcranial physical stimulation device according to any one of claims 1 to 6, characterized in that: The deep part of the brain includes at least one of the basal ganglia, hippocampus, thalamus, amygdala, and nerve nucleus.

10. The transcranial physical stimulation device according to claim 2, characterized in that: The frequency difference between the first electric field and the second electric field is 40 Hz, and the first frequency is also 40 Hz.

11. The transcranial physical stimulation device according to any one of claims 1 to 7, characterized in that: Each electrode is a flexible transparent electrode.

12. The transcranial physical stimulation device according to claim 11, characterized in that: Each electrode is adhered to the scalp via a conductive transparent gel whose transmittance to near-infrared light of 620 nm to 1080 nm is maintained at 70% to 90%.

13. The transcranial physical stimulation device according to any one of claims 1 to 7, characterized in that: The phototherapy unit also includes a head cap, on the inside of which are disposed a plurality of near-infrared light source assemblies, which are configured to emit pulsed light to the treatment object, the wavelength of the pulsed light being 620nm-1080nm, and the radiation range of the pulsed light of each near-infrared light source assembly including at least part of the hippocampus and overlapping at the hippocampus to form a second overlapping area.

14. The transcranial physical stimulation device according to claim 13, characterized in that: The second overlapping region at least partially overlaps with an action region of the first electric field or the second electric field.

Citation Information

Patent Citations

  • Method and a system for optimizing the configuration of multisite transcranial current stimulation and a computer-readable medium and a computer program

    CN105916547A

  • Devices, systems, and methods for stimulation therapy

    CN114522341A

  • Light treatment device for treating psychological disorders including depression

    CN115212469A

  • Customized transcranial alternating current stimulation device and method

    CN116407766A

  • Nerve regulation system for treating mental disorders and use thereof

    CN118543028A

Cited By

  • Transcranial physical stimulation apparatus for treating diseases related to target site of brain

    WO2026060925A1